Dr Andrew Yam

Dr Andrew Yam

Research Associate

22 November 2023

PhD

Garvan Institute of Medical Research, Darlinghurst NSW 2010

St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney

2017

Fellow of the Royal Australasian College of Physician (FRACP)

2005 – 2008

Bachelor of Medicine and Bachelor of Surgery (Honours)  

The University of Sydney

1999 - 2002

Bachelor of Science Honours Class 1 – Medical Microbiology and Immunology

UNSW Sydney

Science
School of Biotech & Biomolecular Science

Dr Andrew Yam is an early-career medical researcher in the Innate and Tumour Immunology laboratory, School of Biotechnology and Biomolecular Sciences, UNSW, and Immune Biotherapies Program, Garvan Institute of Medical Research . Andrew is also a consultant clinical medical oncologist at The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney, treating solid tumours, and is a sub-investigator for multiple phase 1-3 clinical trials. 

Andrew completed undergraduate studies at UNSW and his postgraduate medical degree at the University of Sydney. After obtaining this Fellowship at the Royal Australasian College of Physicians (FRACP).  Andrew completed his PhD at the Innate and Tumour Immunology Lab under the supervision of A/Prof Tatyana Chtanova. His PhD explored the role of microbial infections had in converting the tumour microenvironment from a chronic to acute inflammatory response. He developed and tested the bioparticle therapy in pre-clinical cancer models, and the results of this work were published in Yam et al. ( 2023) Cancer Research. Andrew’s current research is harnessing the anti-cancer microbial inflammation to fight cancers and protect against tumour recurrence with currently used immunotherapies and chemotherapies.  Andrew’s research is supported by the Phil Salter Immuno-oncology Fellowship, UNSW Triple-I seed grant, St Vincent’s Clinic Research Foundation Grant, and Estee Lauder Breast Cancer award.

Location
UNSW Kensington Campus, Level 3 West Bioscience South Building E26, The Kinghorn Cancer Centre, 370 Victoria St Darlinghust NSW 2010 Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst NSW 2010
  • Journal articles | 2025
    Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218
    Journal articles | 2024
    Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', The Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6
    Journal articles | 2024
    Yam AO; Jakovija A; Gatt C; Chtanova T, 2024, 'Neutrophils under the microscope: neutrophil dynamics in infection, inflammation, and cancer revealed using intravital imaging', Frontiers in Immunology, 15, http://dx.doi.org/10.3389/fimmu.2024.1458035
    Journal articles | 2023
    John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677
    Journal articles | 2023
    Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398
    Journal articles | 2023
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104
    Journal articles | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, 'Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy', Cancer Research, 83, pp. 1315 - 1328, http://dx.doi.org/10.1158/0008-5472.CAN-21-4025
    Journal articles | 2022
    Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552
    Journal articles | 2021
    Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European Urology Oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002
    Journal articles | 2020
    Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557
    Journal articles | 2020
    Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120
    Journal articles | 2020
    Yam A; Bailey J; Lin F; Jakovija A; Counoupas C; Triccas J; Gunzer M; Bald T; Grey S; Chtanova T, 2020, 'Microbial activation converts neutrophils into anti-tumor effectors', , http://dx.doi.org/10.1101/2020.08.21.259051
    Journal articles | 2020
    Yam AO; Chtanova T, 2020, 'Imaging the neutrophil: Intravital microscopy provides a dynamic view of neutrophil functions in host immunity', Cellular Immunology, 350, http://dx.doi.org/10.1016/j.cellimm.2019.01.003
    Journal articles | 2019
    Yam AO; Chtanova T, 2019, 'The ins and outs of chemokine-mediated immune cell trafficking in skin cancer', Frontiers in Immunology, 10, http://dx.doi.org/10.3389/fimmu.2019.00386
    Journal articles | 2017
    Yam A; Barnet M; Mersiades A; Gao B; Kao S; Boyer M; Hui R; Nagrial A, 2017, 'P3.02c-055 Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies', Journal of Thoracic Oncology, 12, pp. S1308 - S1308, http://dx.doi.org/10.1016/j.jtho.2016.11.1850
    Journal articles | 2013
    Tan B; Zammit NW; Yam A; Slattery RM; Walters SN; Malle E; Grey ST, 2013, 'Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor êb and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells', Diabetologia, 56, pp. 520 - 532, http://dx.doi.org/10.1007/s00125-012-2784-x
    Journal articles | 2009
    Yam AO; Andresen D; Kesson AM; Isaacs D, 2009, 'Incidence of sterile cerebrospinal fluid pleocytosis in infants with urinary tract infection', Journal of Paediatrics and Child Health, 45, pp. 364 - 367, http://dx.doi.org/10.1111/j.1440-1754.2009.01502.x
    Journal articles | 2008
    Liuwantara D; Gunton J; Yam A; Walters S; Marino E; McShea A; Grey S, 2008, 'GENERATING ISLET ALLOGRAFT TOLERANCE BY BLOCKING NF-KB ACTIVATION AND PREVENTING APOPTOSIS.', Transplantation, 86, pp. 18 - 18, http://dx.doi.org/10.1097/01.tp.0000332732.20615.8f
    Journal articles | 2006
    Liuwantara D; Elliot M; Smith MA; Yam A; Walters SN; Marino E; McShea A; Grey S, 2006, 'Nuclear Factor-KB regulates beta-cell death - A critical role for A20 in beta-cell protection', Diabetes, 55, pp. 2491 - 2501
    Journal articles | 2003
    Ritchie AJ; Yam A; Tanabe K; Rice SA; Cooley MA, 2003, 'Modification of in viro and in vitro T- and B-Cell-Mediated Immune Responses by the Pseudomonas aeruginosa Quorum-Sensing Molecule N-(3-Oxododecanoyl)-L-Homoserine Lactone', Infection and Immunity, 71, pp. 4421 - 4431
    Journal articles | 2003
    Ritchie AJ; Yam AOW; Tanabe KM; Rice SA; Cooley MA, 2003, 'Modification of in vivo and in vitro T- and B-cell-mediated immune responses by the Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-L-homoserine lactone', INFECTION AND IMMUNITY, 71, pp. 4421 - 4431, http://dx.doi.org/10.1128/IAI.71.8.4421-4431.2003
  • Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Data from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.c.6599657
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027266
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027266.v1
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 2 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027263
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 2 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027263.v1
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 3 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027260
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 3 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027260.v1
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 4 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027257
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 4 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027257.v1
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Data from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027254
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Data from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027254.v1
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Table 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027251
    Other | 2024
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Table 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027251.v1
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.c.6599657.v1
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633202
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633202.v1
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633199
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633199.v1
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633196
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633196.v1
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633193
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633193.v1
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Supplementary Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633187
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Supplementary Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633187.v1
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633184
    Other | 2023
    Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633184.v1
    Conference Abstracts | 2022
    Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166
    Conference Abstracts | 2021
    Lau B; Crumbaker M; Yam AOW; Marastoni S; Luckhurst M; O'Grady A; Wouters B; Joshua AM, 2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.114
    Conference Abstracts | 2021
    Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103
    Conference Papers | 2020
    Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2020
    Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
    Conference Papers | 2017
    Yam A; Barnet M; Mersiades A; Gao B; Kao S; Boyer M; Hui R; Nagrial A, 2017, 'Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, pp. S1308 - S1308, http://dx.doi.org/10.1016/j.jtho.2016.11.1850
    Conference Papers | 2016
    Yam AO; Mersiadis A; Gao B; Hui R; Nagrial A, 2016, 'INCIDENCE AND GRADE OF PNEUMONITIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 71 - 72
    Conference Papers | 2007
    Liuwantara D; Elliot M; Smith M; Walters SN; Marino E; Yam AO; Mcshea A; Grey ST, 2007, 'Nf-kb regulates b-cell death: A critical role for early immediate response genes in b-cell protection', in DIABETES, AMER DIABETES ASSOC, IL, Chicago, pp. A411 - A412, presented at 67th Annual Meeting of the American-Diabetes-Association, IL, Chicago, 22 June 2007 - 26 June 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000246930202515&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

I am a primary investigator for the following grants

 

2024

UNSW Triple I Seed Grant $75 000

St Vincent’s Clinic Foundation Seed Grant $50 000

 

I am a co-investigator for the following grants

2023

Tour de Cure Grant  Developing novel immune therapy to fight triple negative breast cancer

UNSW Cancer Theme Seed Grant Scheme Dissecting crosstalk between neutrophils and T cells in microbial therapy of pancreatic cancer

2022

National Breast Cancer Foundation  - Investigator Initiated Scheme

Harnessing the innate immune system to develop new therapies for breast cancer

2019

 National Breast Cancer Foundation – Investigator Initiated Scheme

Developing novel innate-based immunotherapies in triple negative breast cancer

2023

Estée Lauder Breast Cancer Award

2020

Australian and New Zealand Society for Immunology Career Advancement Award

The Kinghorn Postdoctoral Award

 2018-2020

Phillip Salter Immuno-Oncology Fellowship, The Kinghorn Cancer Centre

2018

Beverley Alt Education Grant, The Kinghorn Cancer Centre

2017-2020

PhD Research Training Program (RTP) Scholarship – University of New South Wales

2017

Royal Australasian College of Physicians (RACP) Research Entry Fellows Scholarship